1
Reisner Yair: Durable engraftment and development of human hematopoietic lineages in normal mammals.. Yeda Res & Dev, July 24, 1991: EP0438053-A1 (23 worldwide citation)

A non-human chimeric mammal M4 having long-term stable xenogeneic hematopoietic cells, is obtained by doubly transplanting a mammal M1, the hematopoietic cells of which have been substantially suppressed or destroyed, with hematopoietic cells from at least two different sources, at least one of thes ...


2
Reisner Yair: Durable engraftment of human tissue and cells in normal mammals.. Yeda Res & Dev, December 9, 1992: EP0517199-A1 (15 worldwide citation)

A non-human chimeric mammal M4 having long-term stable xenogeneic tissues or cells other than hematopoietic cells, is obtained by doubly transplanting a mammal M1, the hematopoietic cells of which have been substantially suppressed or destroyed, with tissue or cells other than hematopoietic cells or ...


3
Reisner Yair, Dagan Shlomo: Anticorps monoclonaux humains se fixant sur lantigene de surface de lhepatite b, Human monoclonal antibodies to the hepatitis b surface antigen. Yeda Research And Development, Xtl Biopharmaceuticals, Yeda Research And Development, Xtl Biopharmaceuticals, SMART & BIGGAR, December 18, 1997: CA2254931 (4 worldwide citation)

Disclosed is a process for obtaining hybridoma cell lines which produce human antibodies capable of binding to the hepatitis B virus surface antigen (HBVsAg), as well as the hybridoma cell lines, and antibodies produced by the cell lines. Also disclosed are various uses of said antibodies in the pre ...


4
Reisner Yair, Dekel Benjamin: Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues. Yeda Research And Development, Reisner Yair, Dekel Benjamin, GE EHRLICH, September 16, 2004: WO/2004/078022 (3 worldwide citation)

A method of treating a disorder associated with pathological organ or tissue physiology or morphology is disclosed. The method is effected by transplanting into a subject in need thereof a therapeutically effective mammalian organ or tissue graft selected not substantially expressing or presenting a ...


5
Reisner Yair: Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance. Yeda Research And Development, Reisner Yair, G E EHRLICH, March 1, 2007: WO/2007/023491 (3 worldwide citation)

The present invention provides a method of treating a disease in a subject in need thereof via non-syngeneic graft administration without or with reduced concomitant graft rejection. The method comprises administering to the subject a therapeutically effective graft being non-syngeneic with the subj ...


6
Reisner Yair, Dekel Benjamin, Eventov Friedman Smadar, Katchman Helena, Shezen Elias, Aronovich Anna, Tchorsh Dalit: Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts. Yeda Research And Development, Reisner Yair, Dekel Benjamin, Eventov Friedman Smadar, Katchman Helena, Shezen Elias, Aronovich Anna, Tchorsh Dalit, GE EHRLICH, July 27, 2006: WO/2006/077592 (2 worldwide citation)

A method of treating a renal, hepatic or enzyme-deficiency disorder in a subject in need thereof is disclosed. The method is effected by transplanting into the subject tissue derived from a human or porcine, kidney or liver, the kidney or liver being at a selected gestational stage.


7
REISNER Yair, LASK Assaf, OPHIR Eran, OR GEVA Noga, COHEN Adva, AFIK Ran, BACHAR LUSTIG Esther, EIDELSTEIN Yaki: UTILISATION DE LYMPHOCYTES T DE MÉMOIRE CENTRALE ANTI-TIERS DANS LE TRAITEMENT CONTRE LA LEUCÉMIE ET LE LYMPHOME, USE OF ANTI THIRD PARTY CENTRAL MEMORY T CELLS FOR ANTI-LEUKEMIA/LYMPHOMA TREATMENT. YEDA RESEARCH AND DEVELOPMENT, REISNER Yair, LASK Assaf, OPHIR Eran, OR GEVA Noga, COHEN Adva, AFIK Ran, BACHAR LUSTIG Esther, EIDELSTEIN Yaki, G E EHRLICH, March 15, 2012: WO/2012/032526 (2 worldwide citation)

A method of treating a disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting a non-syngeneic cell or tissue graft to the subject; and (b) administering to the subject a therapeutically effective amount of an isolated population of cells comprising non-graft vers ...


8
REISNER YAIR: Cellules tolerogeniques derivees de donneurs universels et destinees a induire une tolerance a la transplantation non syngenique, Universale von Spendern stammende tolerogene Zellen zur Induktion von nicht-syngener Transplantationstoleranz, Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance. YEDA RES & DEV, October 24, 2012: EP2514315-A2 (1 worldwide citation)

The present invention relates to tolerogenic cells for use in preventing or reducing graft rejection in a subject, wherein said graft is non-syngeneic with the subject and said tolerogenic cells are CD4+CD25+ cells, and wherein said tolerogenic cells are non-syngeneic with both the subject and the g ...


9
Reisner Yair, Dekel Benjamin, Eventov Friedman Smadar, Katchman Helena, Shezen Elias, Aronovich Anna, Tchorsh Dalit: Disease treatment via developing non-syngeneic graft transplantation. Yeda Research And Development, Reisner Yair, Dekel Benjamin, Eventov Friedman Smadar, Katchman Helena, Shezen Elias, Aronovich Anna, Tchorsh Dalit, G E EHRLICH, April 13, 2006: WO/2006/038211 (1 worldwide citation)

A method of providing a pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function to a mammalian subject is provided. The method comprises transplanting into the subject a developing mammalian pancreatic, lymphoid/hematopietic or pulmonary organ/tissue graft, respectively, thereby ...


10